| Literature DB >> 29563590 |
Seung-Ah Yahng1, Sung-Soo Park2, Young-Woo Jeon2, Jae-Ho Yoon2, Seung-Hwan Shin3, Sung-Eun Lee2, Byung-Sik Cho2, Ki-Seong Eom2, Yoo-Jin Kim2, Seok Lee2, Chang-Ki Min2, Hee-Je Kim2, Seok-Goo Cho2, Dong-Wook Kim2, Woo-Sung Min2, Jong Wook Lee4.
Abstract
Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The reconditioning regimen (TNI-750/ATG) consisted of a single dose of total nodal irradiation (TNI, 750 cGy) and antithymocyte globulin (ATG; Thymoglobulin®, 1.25 mg/kg/day for 3 days). All but one patient achieved successful engraftment of neutrophils (median 12 days, range 5-21) and platelets (median 15 days, range 9-316). Two patients with subsequent secondary GF achieved successful engraftment after a third HSCT from the same MSD. After a median follow-up of 57.4 months (range, 11.2-155.2), the 5-year overall survival and failure-free survival were 95.7% (95% confidence interval [CI] 87.7-100%) and 87.5% (95% CI 75.2-100%), respectively. One patient developed grade II acute graft-versus-host disease (GVHD), and the 2-year cumulative incidence of chronic GVHD was 23.5% (95% CI 8.1-43.5%). This study demonstrated successful outcomes following a second MSD HSCT in SAA after GF, and the results suggest TNI-750/ATG is a feasible reconditioning option. Future studies with larger cohorts will validate our results.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29563590 DOI: 10.1038/s41409-018-0154-0
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483